UBS has downgraded Scor from Buy to Neutral, maintaining a target price of €28.70, citing limitations on dividend payouts due to high gearing, weak capital generation, and Solvency II ratio quality. The reinsurer, the fifth-largest globally, focuses on life and health, property & casualty, and investments, with a commitment to innovation and environmental sustainability. Challenges include sensitivity to natural catastrophes and currency fluctuations, alongside ongoing arbitration regarding the US life portfolio sale to Covea.